Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Seronegative and Seropositive Adult Subjects

NCT05077267 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT05077267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Seronegative and Seropositive Adult Subjects
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Completed
Start date
August 19, 2021
Completion date
October 31, 2023
Enrollment
197 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 disease